NCT05680675已完成不适用
Dual-Tracer Theranostic PET
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Completion of Two PET/CT Scans Per Patient as Dictated by Assigned Arm
研究概览
简要总结
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging techniques and processing algorithms for these tracer pairs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults aged 18 years or greater.
- •willing and able to sign a written informed consent and HIPAA authorization in accordance with local and institutional guidelines.
- •presence of at least 1 measurable lesion ≥ 1 cm in size.
- •willing to have their clinical records reviewed for at least 24 months after enrollment.
- •willing to lie flat on their back in the PET/CT scanner for up to one hour to allow for the imaging data to be obtained.
- •willing to undergo two separate PET/CT exams on different days within 2 weeks of each other.
- •female participants who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans. The serum pregnancy test must be performed within 48 hours prior to research PET imaging. A negative test will be necessary for such patients to undergo research PET imaging. This only applies to Arms 1 and 2, since only males will be included in Arm 3 (only males can get prostate cancer).
- •Arms 1 and 2 only: known or suspected somatostatin receptor-positive neuroendocrine tumor (NET) who could be considered for clinical use of DOTATATE PET/CT imaging under the approved indications for use of this radiopharmaceutical according to published appropriate use criteria. These indications include initial staging after the histologic diagnosis of NET, evaluation of an unknown primary; evaluation of a mass suggestive of NET not amenable to endoscopic or percutaneous biopsy, staging of NET before planned surgery, monitoring of NET seen predominantly on somatostatin receptor (SSTR) PET, evaluation of patients with biochemical evidence and symptoms of a NET, evaluation of patients with biochemical evidence of a NET without evidence on conventional imaging or a prior histologic diagnosis, restaging at time of clinical or laboratory progression without progression on conventional imaging, and new indeterminate lesion on conventional imaging with unclear progression.
- •Arm 3 Only: known or suspected prostate cancer who could be considered for clinical use of PSMA PET/CT imaging under the approved indications for use of this radiopharmaceutical, including patients with suspected metastasis and patients with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
排除标准
- •received somatostatin receptor targeted therapy at any time prior to enrollment will be excluded from the study Arms involving DOTATATE (Arms 1-2).
- •known intolerance or hypersensitivity to any somatostatin analogs will be excluded from the study Arms involving DOTATATE (Arms 1-2).
- •participated in any therapeutic clinical study or received any investigational agent within the last 30 days.
- •known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals
- •require monitored anesthesia for PET/CT scanning.
- •too claustrophobic to undergo PET/CT scanning.
- •exceed the 450 lb. weight limit of the PET/CT scanner.
- •pregnant or currently breast feeding.
结局指标
主要结局
Completion of Two PET/CT Scans Per Patient as Dictated by Assigned Arm
时间窗: PET/CT exams were obtained on two separate days within a two week span.
To obtain PET/CT imaging data suitable for developing new simultaneous dual-tracer PET techniques and processing algorithms for dual-tracer imaging of Fluorine-18 fluorodeoxyglucose (FDG) + Cu64-dodecane tetraacetic acid (DOTA) tyrosine-3-octreotate (TATE) (DOTATATE), FDG + Ga68-DOTATATE, and FDG + Ga68-prostate-specific membrane antigen (PSMA)-11 PET/CT
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
PET/CT Evaluation of Treatment Response in Breast CancerBreast CancerNCT01222416Vanderbilt-Ingram Cancer Center50
已完成
不适用
Use of Integrated PET/CT as a First Line Staging and Re-staging Technique in Oncologic Patient.Lung CancerNCT06168877IRCCS San Raffaele30
已完成
不适用
Evaluation of Preoperative Investigations in Patients With Liver CancerPrimary Liver CancerLiver MetastasisNCT00408122Odense University Hospital77
终止
1 期
Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712Healthy Elderly VolunteersNCT01215552Dart NeuroScience, LLC3
已完成
不适用
Clinical study using positron emission tomography(PET)brain tumor,epilepsy,multiple sclerosis, neuromyelitis,Duchenne musclar dystrophy,Alzheimer's disease,Down Syndrome,HydrocephalusJPRN-UMIN000005626Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata100